Jun 16, 2020
Biohaven Presents NURTEC(TM) (rimegepant) Clinical and Pharmacoeconomic Data at the American Headache Society (AHS) Virtual Annual Scientific Meeting
May 07, 2020
Sosei Heptares Announces Further Scientific Progress with Orexin Agonist Program in Conjunction With Spin-off Companies Orexia and Inexia
Apr 27, 2020
Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC(TM) ODT in the Middle East
Apr 02, 2020
COVID-19 Pandemic in the US May Curtail Uptake of Recent Acute Migraine Market Entrants, Diminishing Specialists' Prelaunch Expectations that Biohaven's Nurtec ODT Would Challenge Allergan's Ubrelvy and Eli Lilly's Reyvow
Feb 27, 2020
Biohaven's NURTEC(TM) ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults
Jan 13, 2020
Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi
Sep 26, 2019
Strong Uptake in the Expanding Preventive-Treated Episodic Migraine Segment Has Propelled Eli Lilly's Third-to-Market Emgality to Second Place in the Anti-CGRP Class Surpassing Teva's Ajovy
Sep 11, 2019
Unimpeded by Allergan's Botox Dominance, Amgen/Novartis' Aimovig, Teva's Ajovy, and Eli Lilly's Emgality Use at the Patient Level is More Robust Within the Episodic Migraine Segment Than Physicians Are Aware of
Mar 21, 2019
New Correlation Between Weight Loss Surgery and Satisfaction with Sex Lives in Patients Highlights Hidden Benefits of Bariatric Surgery, says Dr. Feiz & Associates
Mar 01, 2019
Endo Announces FDA Decision Not to Include Vasopressin on 503B Bulks List
Jan 31, 2019
Sobering Obesity Health Research Highlights Weight Loss Surgery as a Medically Sound Option, says Dr. Feiz & Associates
Jul 17, 2018
Learn About Love: Salimetrics Launches Salivary Oxytocin Testing Service
Apr 09, 2018
Vanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic Dermatitis
Mar 29, 2018
Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery's Orexin-1 (OX1) Antagonist Program
Mar 05, 2018
Lyric Completes Enrollment in Phase 2 PROMOTE Study of LP101 (Ulimorelin) in Enteral Feeding Intolerance
Jan 17, 2018
Lyric Pharma Granted FDA Fast Track Designation for Lead Product Ulimorelin for Enteral Feeding Intolerance (EFI)
Jan 11, 2018
Global Migraine Market Spotlight 2017-2027: Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and Regulatory Events, and Patent Information
Nov 20, 2017
Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine
Nov 16, 2017
Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine
Oct 13, 2017
Aratana Therapeutics Announces Launch of ENTYCE® (capromorelin oral solution)